Last reviewed · How we verify

ORA, Inc. — Portfolio Competitive Intelligence Brief

ORA, Inc. pipeline: 8 marketed, 0 filed, 3 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 3 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Olopatadine Nasal Spray Olopatadine Nasal Spray marketed Selective H1-receptor antagonist / mast cell stabilizer H1 histamine receptor Allergy / Immunology
Systane (r) Ultra Systane (r) Ultra marketed Artificial tear / ocular lubricant Ophthalmology
Patanol Patanol marketed Histamine H1 receptor, Histamine H1 receptor Other
Tears Naturale II Ophthalmic Solution Tears Naturale II Ophthalmic Solution marketed Artificial tear / Lubricating ophthalmic solution Ophthalmology
Prednisolone Acetate 0.12% Prednisolone Acetate 0.12% marketed Corticosteroid Glucocorticoid receptor Ophthalmology
Saline Nasal Spray Saline Nasal Spray marketed Nasal decongestant / saline rinse Otolaryngology / Respiratory
Rohto (r) Hydra Rohto (r) Hydra marketed Ophthalmic lubricant / Artificial tear Ophthalmology
Lastacaft ® Lastacaft ® marketed Selective H1-receptor antagonist (antihistamine) H1 receptor Ophthalmology / Allergy
ST-100 (vezocolmitide) ST-100 (vezocolmitide) phase 3 Wnt pathway inhibitor Porcupine Oncology
PL9643 Ophthalmic Solution PL9643 Ophthalmic Solution phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4 Ophthalmology
Placebo Ophthalmic Solution Placebo Ophthalmic Solution phase 3 Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. LEO Pharma · 2 shared drug classes
  2. University of Sao Paulo · 2 shared drug classes
  3. Federal University of São Paulo · 2 shared drug classes
  4. GlaxoSmithKline · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. University of Chicago · 2 shared drug classes
  7. Allergan · 2 shared drug classes
  8. Alfasigma S.p.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ORA, Inc.:

Cite this brief

Drug Landscape (2026). ORA, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ora-inc. Accessed 2026-05-13.

Related